TABLE 1.
Group | Treatment period 1 (days 1-28)a | Treatment period 2 (days 29-42)a |
---|---|---|
1 | 908, 1,395 mg BID | APV, 1,200 mg BID |
2 | APV, 1,200 mg BID | 908, 1,395 mg BID |
3 | 908, 1,860 mg BID | APV, 1,200 mg BID |
4 | APV, 1,200 mg BID | 908, 1,860 mg BID |
908 and APV were both administered in combination with abacavir (300 mg BID) and lamivudine (150 mg BID).